Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methods to Reduce Hyperemia with Bimatoprost
NCT00348062Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of bimatoprost in Glaucoma and ocular hypertension (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Incidence of Conjunctival Hyperemia at Week 6 and Mean Hyperemia Scale Score at Week 6. Status: completed.
02
Drugs
bimatoprost
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT00348062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00348062.